Grant: Travel Awards - Institute Community Support
University of British Columbia
$1,500.00
Inhibiting lung cancer by targeting disulfide reductase enzymes with a novel small molecule that induces reactive oxygen species
FY 2019-20
Summary
Lung cancer (LC) is the leading cause of cancer deaths worldwide, mainly due to the lack of effective drugs available. Most current therapies are focused on targeting genes mutated in lung cancer; however, tumours may require other, non-mutated genes for survival. The difficult part is identifying these non-mutated genes, especially those that are "druggable". A large-scale screen of ~200,000 compounds revealed a new drug that selectively kills lung cancer but not normal cells. Our research has characterized the effects of this drug and used a new, cutting-edge technology to discover that the drug targets enzymes involved in chemical reactions called redox. By proving how these reactions are essential for cancer survival but not normal lung cells, we can bring this new strategy for therapeutic intervention one step closer to clinical testing. Thus, this project has tremendous potential to shift the current status of lung cancer drug development that may impact a large subset of lung cancer patients, for whom treatment is urgently needed.
Department
Program
Travel Awards - Institute Community Support
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
412153
Name
Johnson Fraser
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Institute of Cancer Research
Projecttitle
Inhibiting lung cancer by targeting disulfide reductase enzymes with a novel small molecule that induces reactive oxygen species
Programtype2
Undefined
Orgnameinp2
University of British Columbia
Cihramount2
$1,500
Cihrequipment2
$0
Programname2
Travel Awards - Institute Community Support
Keyworddelim
Lung Cancer; Oxidative Stress; Proteomics; Target Discovery; Thermal Proteome Profiling
Abstract
Lung cancer (LC) is the leading cause of cancer deaths worldwide, mainly due to the lack of effective drugs available. Most current therapies are focused on targeting genes mutated in lung cancer; however, tumours may require other, non-mutated genes for survival. The difficult part is identifying these non-mutated genes, especially those that are "druggable". A large-scale screen of ~200,000 compounds revealed a new drug that selectively kills lung cancer but not normal cells. Our research has characterized the effects of this drug and used a new, cutting-edge technology to discover that the drug targets enzymes involved in chemical reactions called redox. By proving how these reactions are essential for cancer survival but not normal lung cells, we can bring this new strategy for therapeutic intervention one step closer to clinical testing. Thus, this project has tremendous potential to shift the current status of lung cancer drug development that may impact a large subset of lung cancer patients, for whom treatment is urgently needed.
Competitiondate
201909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Johnson, Fraser
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $1,500~ $0~
